1362850-20-1 Usage
General Description
Seletalisib is a novel small molecule inhibitor of phosphoinositide 3-kinase (PI3K) that has demonstrated potential as a targeted therapy for various types of cancer and autoimmune diseases. As a PI3K inhibitor, seletalisib works by blocking the PI3K signaling pathway, which is involved in regulating cell proliferation, survival, and metabolism. Preclinical studies have shown that seletalisib has anti-tumor activity in several cancer types, including breast, ovarian, and hematologic malignancies. Additionally, seletalisib has shown promise in the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus, by modulating immune cell function. Clinical trials are currently underway to further evaluate the safety and efficacy of seletalisib as a potential treatment for these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1362850-20-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,2,8,5 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1362850-20:
(9*1)+(8*3)+(7*6)+(6*2)+(5*8)+(4*5)+(3*0)+(2*2)+(1*0)=151
151 % 10 = 1
So 1362850-20-1 is a valid CAS Registry Number.
1362850-20-1Relevant articles and documents
CRYSTALLINE FORMS OF SELETALISIB
-
, (2019/01/04)
Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human ΡΒΚδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
